Lantern Pharma falls out of Nasdaq MVLS compliance after market value stays below $35 million

• Lantern Pharma received a Nasdaq notice for noncompliance with Listing Rule 5550(b)(2) after MVLS stayed below $35,000,000 for 30 business days.
• Nasdaq also flagged that the company does not meet Listing Rule requirements under 5550(b)(1) and 5550(b)(3).
• The company has until March 24, 2027 to regain compliance under Nasdaq rules.
• To cure the MVLS breach, MVLS must close at or above $35,000,000 for at least 10 consecutive business days.
• Failure to regain compliance could trigger a delisting notice for its securities from the Nasdaq Capital Market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-045344), on October 01, 2026, and is solely responsible for the information contained therein.